65
Views
1
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

VEGF single nucleotide polymorphisms predict improved outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

, , , , , , , , , & show all
Pages 53-62 | Received 08 Jul 2021, Accepted 20 Feb 2022, Published online: 09 Mar 2022

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34. Jan
  • Johnson DH, S J, Bunn PA. Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32(10):10.
  • Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 1987;34(2):155–166.
  • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–591. Aug
  • Frezzetti D, Gallo M, Maiello MR, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 2017;21(10):959–966. Oct
  • Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;51(2):143–158. Feb
  • Zhai R, Liu G, Zhou W, et al. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008;14(2):612–617. Jan 15
  • Yamamoto Y, Kiyohara C, Ogata-Suetsugu S, et al. Association between genetic polymorphisms involved in the hypoxia-inducible factor pathway and lung cancer risk: a case-control study in Japan. Asia Pac J Clin Oncol. 2017;13(3):234–242. Jun
  • Tu J, Wang S, Zhao J, et al. rs833061 and rs699947 on promoter gene of vascular endothelial growth factor (VEGF) and associated lung cancer susceptibility and survival: a meta-analysis. Med Sci Monit. 2014;20:2520–2526. Dec 3
  • Chen J, Yin JY, Li XP, Wang Y, et al. Association of Wnt-Inducible signaling pathway protein 1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Clin Lung Cancer. 2015;16(4):298–304 e1-2. Jul
  • Lee S, Kang HG, Choi JE, et al. The different effect of VEGF polymorphisms on the prognosis of non-small cell lung cancer according to tumour histology. J Korean Med Sci. 2016;31(11):1735–1741. Nov
  • Ettinger DS, Wood DE, Aggarwal C, OCN, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464–1472. Dec
  • Liu D, Wu C, Jiao Y, et al. WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients. Sci Rep. 2015;5:11114 Jun 9
  • Chen L, Qi H, Zhang L, et al. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients. BMC Cancer. 2018;18(1):1038 Oct 25
  • Xie B, Liu Z, Liu W, et al. DNA methylation and tag SNPs of the BDNF gene in conversion of amnestic mild cognitive impairment into alzheimer's disease: a cross-sectional cohort study. J Alzheimers Dis. 2017;58(1):263–274.
  • Chen Y, Qiu C, Qian S, et al. Lack of association of rs1192415 in TGFBR3-CDC7 with visual field progression: a cohort study in chinese open angle glaucoma patients. Front Genet. 2018;9:488.
  • Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–98. Feb
  • Li Z, Zhang Z, He Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009;19(4):519–523. Apr
  • Mauguen A, Pignon JP, Burdett S, Surrogate Lung Project Collaborative Group, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of Meta-analyses of individual patients' data. Lancet Oncol. 2013;14(7):619–626. Jun
  • Zhao S, Zhang Z, Zhang Y, et al. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. Int J Cancer. 2019;144(11):2854–2866. Jun 1
  • Sun SF, Huang DB, Cao C, et al. Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in chinese population. Med Oncol. 2013;30(1):410.
  • Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(6):856–862. Feb 20
  • Naykoo NA, Dil A, Rasool R, et al. Single nucleotide polymorphisms, haplotype association and tumour expression of the vascular endothelial growth factor (VEGF) gene with lung carcinoma. Gene. 2017;608:95–102. Apr 15
  • Li Y, Liang J, Liu X, et al. Correlation of polymorphisms of the vascular endothelial growth factor gene and the risk of lung cancer in an ethnic han group of North China. Exp Ther Med. 2012;3(4):673–676. Apr
  • Liu C, Zhou X, Zhang Z, et al. Correlation of gene polymorphisms of vascular endothelial growth factor with grade and prognosis of lung cancer. BMC Med Genet. 2020;21(1):86.
  • Liu C, Zhou X, Gao F, et al. Correlation of genetic polymorphism of vascular endothelial growth factor gene with susceptibility to lung cancer. Cancer Gene Ther. 2015;22(6):312–316. Jun
  • Yang F, Tang X, Riquelme E, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011;71(16):5512–5521. Aug 15
  • Pallaud C, Reck M, Juhasz E, et al. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. Lung Cancer. 2014;86(1):67–72. Oct
  • Sullivan I, Riera P, Andrés M, et al. Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis. 2019;22(3):433–440. Aug
  • Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63(4):812–816. Feb 15
  • Lin CC, Wu HC, Tsai FJ, et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology. 2003;62(2):374–377. Aug
  • Loupakis F, Ruzzo A, Salvatore L, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 2011;11:247 Jun 14
  • Sohn BS, Park SJ, Kim JE, et al. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer. Oncology. 2014;87(5):280–292.
  • Scartozzi M, Bianconi M, Faloppi L, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer. 2013;108(5):1126–1132. Mar 19
  • Guan X, Yin M, Wei Q, et al. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010;10:431 Aug 16
  • Slatkin M. Linkage disequilibrium-understanding the evolutionary past and mapping the medical future. Nat Rev Genet. 2008;9(6):477–485. Jun
  • Furuya TK, Jacob CE, Tomitao MTP, et al. Association between polymorphisms in inflammatory response-related genes and the susceptibility, progression and prognosis of the diffuse histological subtype of gastric cancer. Genes (Basel). 2018;9(12):631. Dec 13
  • Sudhesan A, Rajappa M, Chandrashekar L, et al. Vascular endothelial growth factor (VEGF) gene polymorphisms (rs699947, rs833061, and rs2010963) and psoriatic risk in South Indian Tamils. Hum Immunol. 2017;78(10):657–663. Oct
  • Escudier B, Rini BI, Motzer RJ, et al. Genotype correlations with blood pressure and efficacy from a randomized phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015;13(4):328–337 e3. Aug
  • Reck M, Mok TSK, Nishio M, IMpower150 Study Group, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. May
  • Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505–1517.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.